Skip to main content Skip to section navigation Skip to footer
Stock Information
chevron_leftBack to Codexis.com

Holiday shipping and closure information

Learn more.

Featured in CBS News' Economy 4.0

Read the blog
  • Blogs
  • Events
  • Careers
  • Investors
  • Search
  • About Us
    • History
    • Leadership Team
    • Facilities
    • ESG
    • Culture and People
  • Expert Solutions

    Pharma Biocatalysis

    Transform complex, resource-intensive processes into precise, sustainable breakthroughs with biocatalysis that scales from grams to tonnes

    • Enzyme Screening Kits and Panels
    • Tailored Enzymes

    RNA Manufacturing Services

    Evolve beyond solid-phase oligonucleotide synthesis (SPOS) with a modern and efficient approach that delivers higher quality, greater scale, and better manufacturability

    • RNA Ligation Services
    • RNA Sequential Synthesis Services

    Molecular Biology and Diagnostic Applications

    Precision-tuned enzyme solutions enhance fidelity, selectivity, and activity for applications that demand superior performance

    • Bespoke Enzymes
    • R&D Enzyme Services

    Find out more about our solutions

    See our solutions
  • Transformational Technologies
    Transformational Technologies
    • CodeEvolver Technology Platform
    • ECO Synthesis Manufacturing Technology
  • Technical Content
  • Contact Us
Codexis, Inc. IR Overview
  • Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    • TIDES US
  • Presentations
  • Company Info
    • Company Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Information Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Codexis Ethics Helpline
  • Stock Information
  • chevron_leftBack to Codexis.com

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    • TIDES US
  • Presentations
  • Company Info
    • Company Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Information Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Codexis Ethics Helpline
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • TIDES US
May 16, 2022 8:00 am EDT
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
May 5, 2022 4:05 pm EDT
Codexis Reports First Quarter 2022 Financial Results
May 2, 2022 4:35 pm EDT
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
Apr 21, 2022 4:05 pm EDT
Codexis to Report First Quarter 2022 Financial Results on May 5
Apr 21, 2022 8:00 am EDT
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
Apr 12, 2022 8:00 am EDT
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
Mar 1, 2022 4:05 pm EST
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
Feb 24, 2022 4:05 pm EST
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Feb 10, 2022 4:05 pm EST
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
Jan 24, 2022 8:00 am EST
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • …
  • Page 27
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

Let’s redefine what’s possible

Discover the partnership that enables your enzyme-powered innovation — designed for staying power, not just quick wins.

Contact us
  • Jump to
  • About Us
  • Expert Solutions
  • Transformational Technologies
  • Technical Content
  • Blogs
  • Events
  • Careers
  • Investors
  • Help
  • Contact Us
  • Terms of Use
  • Privacy Policy

© 2025 Copyright Codexis

  • Privacy
  • Terms of Use
  • Disclaimer
  • Patents
  • Trademarks
  • Accessibility Statement

Find us on:

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.